MEP10508A - The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation - Google Patents
The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferationInfo
- Publication number
- MEP10508A MEP10508A MEP-105/08A MEP10508A MEP10508A ME P10508 A MEP10508 A ME P10508A ME P10508 A MEP10508 A ME P10508A ME P10508 A MEP10508 A ME P10508A
- Authority
- ME
- Montenegro
- Prior art keywords
- smc
- smooth muscle
- flavopiridol
- proliferation
- glycine
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 title abstract 3
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 150000004777 chromones Chemical class 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 6
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 abstract 4
- 229950010817 alvocidib Drugs 0.000 abstract 4
- 239000004471 Glycine Substances 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 3
- 230000035755 proliferation Effects 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 230000022131 cell cycle Effects 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 208000024248 Vascular System injury Diseases 0.000 abstract 1
- 208000012339 Vascular injury Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 210000002460 smooth muscle Anatomy 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24338099A | 1999-02-01 | 1999-02-01 | |
| US09/468,665 US6399633B1 (en) | 1999-02-01 | 1999-12-21 | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| PCT/US2000/001104 WO2000044362A2 (en) | 1999-02-01 | 2000-01-18 | The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP10508A true MEP10508A (en) | 2010-06-10 |
Family
ID=22918541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-105/08A MEP10508A (en) | 1999-02-01 | 2000-01-18 | The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6399633B1 (id) |
| EP (1) | EP1150746B1 (id) |
| JP (1) | JP4755759B2 (id) |
| KR (1) | KR100793047B1 (id) |
| CN (1) | CN1219556C (id) |
| AP (1) | AP1469A (id) |
| AR (1) | AR042569A1 (id) |
| AT (1) | ATE275428T1 (id) |
| AU (1) | AU777368B2 (id) |
| BG (1) | BG65151B1 (id) |
| BR (1) | BR0007911A (id) |
| CA (1) | CA2360668C (id) |
| CR (1) | CR6448A (id) |
| CZ (1) | CZ300395B6 (id) |
| DE (1) | DE60013555T2 (id) |
| DK (1) | DK1150746T3 (id) |
| EA (1) | EA004786B1 (id) |
| EE (1) | EE04851B1 (id) |
| ES (1) | ES2226792T3 (id) |
| HK (1) | HK1042445B (id) |
| HR (1) | HRP20010521A2 (id) |
| HU (1) | HU229263B1 (id) |
| ID (1) | ID30180A (id) |
| IL (1) | IL144668A (id) |
| ME (1) | MEP10508A (id) |
| NO (1) | NO330512B1 (id) |
| NZ (1) | NZ512822A (id) |
| OA (1) | OA11755A (id) |
| PL (1) | PL197693B1 (id) |
| PT (1) | PT1150746E (id) |
| RS (1) | RS50242B (id) |
| SI (1) | SI1150746T1 (id) |
| SK (1) | SK286747B6 (id) |
| TR (1) | TR200102223T2 (id) |
| TW (1) | TWI273907B (id) |
| UA (1) | UA73110C2 (id) |
| WO (1) | WO2000044362A2 (id) |
| ZA (1) | ZA200105596B (id) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102480D0 (en) * | 2001-01-31 | 2001-03-14 | Cyclacel Ltd | Marker |
| CN100381437C (zh) * | 2002-04-17 | 2008-04-16 | 赛特凯恩蒂克公司 | 化合物、组合物和方法 |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US20040106647A1 (en) * | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
| US20040082613A1 (en) * | 2002-06-28 | 2004-04-29 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
| WO2004022097A1 (en) * | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| AU2004229501B2 (en) | 2003-04-11 | 2011-08-18 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
| US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
| US20050048617A1 (en) | 2003-08-18 | 2005-03-03 | Medimmune, Inc. | Humanization of antibodies |
| EP2422811A2 (en) | 2004-10-27 | 2012-02-29 | MedImmune, LLC | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| EP1869192B1 (en) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Framework-shuffling of antibodies |
| CA2613512A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
| GB2443576A (en) * | 2005-07-15 | 2008-05-07 | Sahajanand Biotech Private Ltd | Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis |
| JP2008255008A (ja) * | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
| KR101431279B1 (ko) * | 2005-07-29 | 2014-08-20 | 리스버로직스 코퍼레이션 | 복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달 |
| EA021255B1 (ru) | 2006-08-28 | 2015-05-29 | Киова Хакко Кирин Ко., Лимитед | Антагонистические моноклональные антитела человека, специфичные в отношении light человека |
| ES2454966T3 (es) | 2007-02-01 | 2014-04-14 | Resverlogix Corp. | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
| JP5456658B2 (ja) | 2007-03-30 | 2014-04-02 | メディミューン，エルエルシー | 抗体製剤 |
| RU2520098C2 (ru) | 2008-06-26 | 2014-06-20 | Ресверлоджикс Корп. | Способы получения производных хиназолинона |
| WO2010079431A2 (en) | 2009-01-08 | 2010-07-15 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| NZ595747A (en) | 2009-03-18 | 2015-06-26 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
| KR20190091564A (ko) | 2009-04-22 | 2019-08-06 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| EP2593099A1 (en) | 2010-07-12 | 2013-05-22 | DKFZ Deutsches Krebsforschungszentrum | Wogonin for the prevention and therapy of cardiac hypertrophy |
| DK2668210T3 (da) | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | Anti-kit antistoffer og anvendelser deraf |
| PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
| US9334332B2 (en) | 2012-07-25 | 2016-05-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
| AU2013329311A1 (en) | 2012-10-09 | 2015-04-30 | Igenica Biotherapeutics, Inc. | Anti-C16orf54 antibodies and methods of use thereof |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| CA2914369C (en) | 2013-06-06 | 2023-02-14 | Igenica Biotherapeutics, Inc. | Anti-c10orf54 antibodies and uses thereof |
| CN105764526B (zh) | 2013-08-26 | 2020-12-15 | 生物技术研发公司 | 编码抗唾液酸化路易斯a抗原的人抗体的核酸 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| AU2015271685B2 (en) | 2014-06-04 | 2021-02-18 | Biontech Research And Development, Inc. | Human monoclonal antibodies to ganglioside GD2 |
| SG11201704752WA (en) | 2014-12-11 | 2017-07-28 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
| PT3265123T (pt) | 2015-03-03 | 2023-02-01 | Kymab Ltd | Anticorpos, usos e métodos |
| JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
| MX2017013383A (es) | 2015-04-20 | 2017-12-07 | Tolero Pharmaceuticals Inc | Prediccion de respuesta a alvocidib mediante perfilado mitocondrial. |
| TR201911032T4 (tr) | 2015-05-18 | 2019-08-21 | Tolero Pharmaceuticals Inc | Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları. |
| AU2016301315C1 (en) | 2015-08-03 | 2022-07-07 | Sumitomo Pharma Oncology, Inc. | Combination therapies for treatment of cancer |
| MX2018006613A (es) | 2015-12-02 | 2019-01-30 | Stcube & Co Inc | Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos. |
| JP7227007B2 (ja) | 2015-12-02 | 2023-02-21 | ストサイエンシス， インコーポレイテッド | グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体 |
| KR102466192B1 (ko) | 2016-08-23 | 2022-11-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 간세포성 암종의 치료를 위한 조합 요법 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| WO2018170447A1 (en) | 2017-03-16 | 2018-09-20 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
| JP2020522512A (ja) | 2017-05-31 | 2020-07-30 | ストキューブ アンド シーオー．， インコーポレイテッド | Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法 |
| WO2018222689A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| US11542331B2 (en) | 2017-06-06 | 2023-01-03 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| WO2019073069A1 (en) | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN) |
| CN112740043A (zh) | 2018-07-20 | 2021-04-30 | 皮埃尔法布雷医药公司 | Vista受体 |
| WO2020117988A1 (en) | 2018-12-04 | 2020-06-11 | Tolero Pharmaceuticals, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| CN113559244B (zh) * | 2021-08-02 | 2023-12-26 | 华中科技大学同济医学院附属协和医院 | Ctrp13脂肪因子的新用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN164232B (id) * | 1986-04-11 | 1989-02-04 | Hoechst India | |
| US5284856A (en) * | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
| US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
| US5908934A (en) | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
| EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
-
1999
- 1999-12-21 US US09/468,665 patent/US6399633B1/en not_active Expired - Fee Related
-
2000
- 2000-01-18 AP APAP/P/2001/002218A patent/AP1469A/en active
- 2000-01-18 ES ES00909918T patent/ES2226792T3/es not_active Expired - Lifetime
- 2000-01-18 UA UA2001075481A patent/UA73110C2/uk unknown
- 2000-01-18 AT AT00909918T patent/ATE275428T1/de active
- 2000-01-18 OA OA1200100196A patent/OA11755A/en unknown
- 2000-01-18 EE EEP200100385A patent/EE04851B1/xx not_active IP Right Cessation
- 2000-01-18 PL PL350735A patent/PL197693B1/pl not_active IP Right Cessation
- 2000-01-18 DE DE60013555T patent/DE60013555T2/de not_active Expired - Lifetime
- 2000-01-18 EA EA200100742A patent/EA004786B1/ru not_active IP Right Cessation
- 2000-01-18 CZ CZ20012804A patent/CZ300395B6/cs not_active IP Right Cessation
- 2000-01-18 ME MEP-105/08A patent/MEP10508A/xx unknown
- 2000-01-18 AU AU32098/00A patent/AU777368B2/en not_active Ceased
- 2000-01-18 SI SI200030517T patent/SI1150746T1/xx unknown
- 2000-01-18 NZ NZ512822A patent/NZ512822A/en not_active IP Right Cessation
- 2000-01-18 RS YU54401A patent/RS50242B/sr unknown
- 2000-01-18 KR KR1020017009716A patent/KR100793047B1/ko not_active IP Right Cessation
- 2000-01-18 IL IL14466800A patent/IL144668A/xx not_active IP Right Cessation
- 2000-01-18 DK DK00909918T patent/DK1150746T3/da active
- 2000-01-18 JP JP2000595666A patent/JP4755759B2/ja not_active Expired - Fee Related
- 2000-01-18 PT PT00909918T patent/PT1150746E/pt unknown
- 2000-01-18 ID IDW00200101696A patent/ID30180A/id unknown
- 2000-01-18 CA CA002360668A patent/CA2360668C/en not_active Expired - Fee Related
- 2000-01-18 WO PCT/US2000/001104 patent/WO2000044362A2/en active IP Right Grant
- 2000-01-18 HU HU0200804A patent/HU229263B1/hu not_active IP Right Cessation
- 2000-01-18 CN CNB008032513A patent/CN1219556C/zh not_active Expired - Fee Related
- 2000-01-18 BR BR0007911-1A patent/BR0007911A/pt not_active Application Discontinuation
- 2000-01-18 EP EP00909918A patent/EP1150746B1/en not_active Expired - Lifetime
- 2000-01-18 SK SK1086-2001A patent/SK286747B6/sk not_active IP Right Cessation
- 2000-01-18 TR TR2001/02223T patent/TR200102223T2/xx unknown
- 2000-01-25 TW TW089101215A patent/TWI273907B/zh not_active IP Right Cessation
- 2000-02-01 AR ARP000100420A patent/AR042569A1/es not_active Application Discontinuation
-
2001
- 2001-07-05 NO NO20013335A patent/NO330512B1/no not_active IP Right Cessation
- 2001-07-06 ZA ZA200105596A patent/ZA200105596B/en unknown
- 2001-07-11 HR HR20010521A patent/HRP20010521A2/hr not_active Application Discontinuation
- 2001-07-27 BG BG105751A patent/BG65151B1/bg unknown
- 2001-08-23 CR CR6448A patent/CR6448A/es not_active Application Discontinuation
-
2002
- 2002-05-31 HK HK02104062.3A patent/HK1042445B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP10508A (en) | The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation | |
| Schuppan et al. | Hepatic fibrosis: from bench to bedside | |
| WO2008073670A3 (en) | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor | |
| ATE369817T1 (de) | Vorrichtung zur abgabe von therapeutischen wirkstoffen | |
| NO20063373L (no) | CD40-antistoff-formuleringer og fremgangsmater | |
| IL172705A0 (en) | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases | |
| WO2004110302A3 (en) | Methods of delivering anti-restenotic agents from a stent | |
| BRPI0408999A (pt) | comprimidos prensados de multiparticulados de liberação oral prolongada | |
| DE602004032149D1 (de) | Oros-push-stick für die kontrollierte abgabe von wirkstoffen | |
| JP2003533496A5 (id) | ||
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| DE69435318D1 (de) | Therapeutische inhibitoren der zellen der glatten gefässmuskulatur | |
| AR026197A1 (es) | Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina | |
| DK0856312T3 (da) | Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme | |
| BR0008443A (pt) | Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética | |
| AU692307B2 (en) | Quinazolinone pharmaceuticals and use thereof | |
| ATE359798T1 (de) | Verwendungvon dextransulfat zur behandlung von ibmir | |
| HK1046094A1 (en) | Ppar delta inhibitors for the treatment of cardiovascular diseases | |
| NO20021410L (no) | Forebygging og behandling av blodkoagulasjons-relaterte sykdommer | |
| REED et al. | Vascular reactions in chronically inflamed skin: III. Action of histamine, the histamine releaser 48-80, and monoethanolamine nicotinate (Nicamin) | |
| Ferrell et al. | The role of the endothelium in mediating the actions of ATP, adenosine and acetylcholine on flow through blood vessels in the rabbit knee joint. | |
| Chang et al. | Differential contributions of nitric oxide synthase isoforms at hippocampal formation to negative feedback regulation of penile erection in the rat | |
| RU2010144554A (ru) | Средство для предотвращения и/или лечения сосудистых заболеваний | |
| IL110888A (en) | Pharmaceutical compositions for the treatment of liver diseases comprising a vasodilating compound | |
| UA3373U (uk) | Спосіб моделювання інфаркту міокарда |